NICE stiff-arms Alexion's $552K Strensiq; Mylan falls under DOJ scrutiny for generic prices;

> The cost-effectiveness watchdogs at the U.K.'s National Institute for Health and Care Excellence said "no go" to Alexion's ($ALXN) $552,000 price on its new rare disease med Strensiq. Report

> The U.S. Justice Department issued a subpoena to Mylan ($MYL), the most recent of a group of drugmakers to come under scrutiny for prices of their generic meds. Report

> Biofrontera won approval in Switzerland for Ameluz, its new skin cancer med; the drug is also under review at the FDA. Release (PDF)

And Finally... Stallergenes is recalling allergy immunotherapies shipped from a plant in Antony, France, after August 13. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.